Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Michael Schmidt Guggenheim Securities, LLC, Research Division. All right. So daraxonrasib, obviously, there's been a lot of focus on the upcoming phase. The first randomized Phase ...

Merck no longer in talks to buy Revolution Medicines

The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion.
The Bakersfield Californian

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that ...
Seeking Alpha

Exclusive BAC Article: Revolution Medicines; Positive Phase 1 Data 2nd-Line mPDAC RAS-Mutant Patients, Phase 3 Topline Data 2026, Expansions Into Adjuvant Setting And Catalysts

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Revolution Medicines (RVMD). The reason why I want to go over this biotech next is because ...
Hosted on MSN

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

Jan 7 (Reuters) - AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Shares of ...